Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: J Neurosci Res. 2015 Jul 8;93(10):1592–1599. doi: 10.1002/jnr.23622

Table I.

Primary Antibodies Used

Antigen Description of Immunogen Source, host species, catalog No., clone or lot No., RRID Concentration used (μg/ml) Primary antibody blocking solution
β-Actin C-terminal actin fragment: Ser-Gly-Pro-Ser-Ile-Val-His-Arg-Lys-Cys-Phe Sigma-Aldrich (St. Louis, MO), rabbit polyclonal, A2066, AB_476693 0.2 3% Nonfat rrilk-PBS
0.1% Tween-20
pERK1/2 A synthetic phosphopeptide corresponding to residues surrounding Thr202/Tyr204 of human p44 MAP kinase Cell Signaling Technology (Beverly, MA), rabbit polyclonal, 9101S, lot No. 28, AB_331646 1 3% Nonfat milk-PBS
0.1% Tween-20
ERK1/2 A synthetic peptide corresponding to a sequence in the C-terminus of rat p44 MAP Kinase Cell Signaling Technology, rabbit polyclonal, 9102S, lot No. 23, AB_10695746 0.5 3% Nonfat milk-PBS
0.1% Tween-20
pJNK A synthetic phosphopeptide corresponding to residues surrounding Thr183/Tyr185 of human SAPK/JNK. Cell Signaling Technology, rabbit polyclonal, 9251L, lot No. 21, AB_2140557 1 3% Nonfat milk-PBS
0.1% Tween-20
JNK A recombinant human JNK2 protein Cell Signaling Technology, rabbit polyclonal, 9252S, lot No. 12, AB_10693936 0.5 3% Nonfat milk-PBS
0.1% Tween-20
HHS Vulnerability Disclosure